Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
GroundBBreaker 301 trial: what clinicians have said so far
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma
- NCT07836530 ↗
- Recruiting
- BeOne Medicines
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on GroundBBreaker 301 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GroundBBreaker 301 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Phase 3 Study to Investigate the Efficacy and Safety of BGB-B2033 Compared With Investigator Choice of Sorafenib or Lenvatinib in Patients With Hepatocellular Carcinoma That Progressed Upon Prior Systemic Treatment
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Hepatocellular Carcinoma; Liver Cancer
- Interventions
- BGB-B2033; Lenvatinib; Sorafenib
- Arms
- BGB-B2033 · Experimental
- Investigator's choice: Lenvatinib OR sorafenib · Active comparator
- Enrollment
- 492 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- BeOne Medicines
- Start
- Oct 23, 2026
- Primary completion
- Sep 21, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07836530 · updated Nov 10, 2026